secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-01-07T23:59:59+00:00
Accession:  0001437749-26-000695
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech regains Nasdaq compliance, avoiding delisting
---------------------------------------------------------------

- Nasdaq staff notified Panel on Jan 6, 2026 that Moleculin regained compliance with Listing Rule 5550(b)(1) (min $2.5M equity).
- Company received delist determination on Nov 20, 2025 and had appealed; hearing now cancelled.
- Company is in compliance with all applicable Nasdaq continued listing standards as of Jan 6, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926000695/0001437749-26-000695-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926000695/mbrx20260106_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-000695

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer